title: [Effectiveness and cost of 5-HT3-antagonists in acute chemotherapy-induced emesis. Health-economic analysis based on current meta-analytic data].
abstract: BACKGROUND
  Cost containment measures in hospitals suspect the efficiency of 5-HT3-receptor antagonists (5-HT3-RA) in treating chemotherapy-induced emesis.
  
  
  METHODS
  This paper compares the cost-efficacy of acute antiemetic interventions both for high and moderate emetogenic cancer treatments. The cost-efficacy-analysis is based on a recent metaanalysis comparing metoclopramide (MCP)- and 5-HT3-RA-containing antiemetic regimens both in comedication with corticosteroids. Total costs for treating moderate emetogenic cancer treatments sum up to DM 53.- for MCP-regimens and DM 55.- for 5-HT3-RA resp. In high emetogenic cancer treatments total costs for MCP-regimens are DM 76.- and DM 61.- for 5-HT3-RA. Total costs for fully controlled patients in moderate emetogenic cancer treatments are DM 77.- for MCP and DM 71.- for 5-HT3-RA. In high emetogenic cancer treatments costs for the fully controlled patient with MCP-regimens are DM 126.- and DM 79.- with 5-HT3-RA.
  
  
  CONCLUSIONS
  Even under mere economical considerations 5-HT3-RAs should be prescribed in treating acute chemotherapy-induced emesis.
authors.affiliation: Institut für Health Economics and Disease Management, Celle.
authors.forename: B
authors.initials: B
authors.lastname: Brüggenjürgen
authors.forename: A
authors.initials: A
authors.lastname: du Bois
mesh_terms: D000932:Antiemetics / Q000191:economics* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D005858:Germany; D006801:Humans; D008787:Metoclopramide / Q000191:economics / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000191:economics* / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D008787:Metoclopramide; D017367:Selective Serotonin Reuptake Inhibitors
vernacular_title: Wirksamkeit und Kosten der 5-HT3-Antagonisten beim akuten chemotherapieinduzierten Erbrechen. Gesundheitsökonomische Analyse auf der Basis aktueller metaanalytischer Daten.